Quantitative Investment Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 12.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 75,200 shares of the company’s stock after purchasing an additional 8,600 shares during the quarter. Quantitative Investment Management LLC’s holdings in Eli Lilly and were worth $6,188,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of LLY. Acrospire Investment Management LLC lifted its position in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Point72 Asia Hong Kong Ltd lifted its position in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Eli Lilly and in the 2nd quarter valued at about $148,000. Cornerstone Advisors Inc. lifted its position in Eli Lilly and by 18.4% in the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after purchasing an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC lifted its position in Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after purchasing an additional 176 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) opened at $83.29 on Friday. The firm has a market cap of $91,710.20, a P/E ratio of 20.36, a PEG ratio of 1.83 and a beta of 0.34. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 1 year low of $64.18 and a 1 year high of $89.09.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm posted $0.88 earnings per share. research analysts predict that Eli Lilly and Company will post 4.22 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.
TRADEMARK VIOLATION WARNING: “Quantitative Investment Management LLC Purchases 8,600 Shares of Eli Lilly and Company (LLY)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/quantitative-investment-management-llc-purchases-8600-shares-of-eli-lilly-and-company-lly.html.
In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 770,000 shares of company stock worth $64,669,850. 0.20% of the stock is currently owned by insiders.
Several analysts recently weighed in on the stock. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Barclays PLC raised their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Berenberg Bank reissued a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Cowen and Company reissued a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $89.76.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.